Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2

Status

Active not recruiting 3Terminated 2Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × cabazitaxel × Clear all
NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

OHSU Knight Cancer Institute

Phase 1/2 Active not recruiting
37 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT05340374 2025-04-06

LuCAB

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
35 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting
51 enrolled

Carcinoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡